BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Lymphoma AND RBM10, GPATC9, 8241, ENSG00000182872, CTD-2522E6_5, GPATCH9, KIAA0122, P98175, MGC1132, DXS8237E, ZRANB5, MGC997 AND Clinical Outcome
745 results:

  • 1. Biological signatures of the International Prognostic Index in diffuse large B-cell lymphoma.
    Wang Y; Shi Q; Shi ZY; Tian S; Zhang MC; Shen R; Fu D; Dong L; Yi HM; Ouyang BS; Mu RJ; Cheng S; Wang L; Xu PP; Zhao WL
    Blood Adv; 2024 Apr; 8(7):1587-1599. PubMed ID: 38170757
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. RNA-seq-based miRNA signature as an independent predictor of relapse in pediatric B-cell acute lymphoblastic leukemia.
    Kubota H; Ueno H; Tasaka K; Isobe T; Saida S; Kato I; Umeda K; Hiwatari M; Hasegawa D; Imamura T; Kakiuchi N; Nannya Y; Ogawa S; Hiramatsu H; Takita J
    Blood Adv; 2024 Mar; 8(5):1258-1271. PubMed ID: 38127276
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Suspected primary bone marrow T-cell lymphoid neoplasia causing paraneoplastic hypercalcemia in 11 dogs (2014-2021).
    Portanova A; Rout ED; Avery AC; Viall AK
    J Am Vet Med Assoc; 2024 Mar; 262(3):1-9. PubMed ID: 37922707
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. PHF6-altered T-ALL Harbor Epigenetic Repressive Switch at Bivalent Promoters and Respond to 5-Azacitidine and Venetoclax.
    Pinton A; Courtois L; Doublet C; Cabannes-Hamy A; Andrieu G; Smith C; Balducci E; Cieslak A; Touzart A; Simonin M; Lhéritier V; Huguet F; Balsat M; Dombret H; Rousselot P; Spicuglia S; Macintyre E; Boissel N; Asnafi V
    Clin Cancer Res; 2024 Jan; 30(1):94-105. PubMed ID: 37889114
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Whole exome germline sequencing in early-onset prostate cancer patients: Genomic findings and clinical outcomes.
    Siegelmann-Danieli N; Neiman V; Bareket-Samish A; Berger R; Peretz A; Alapi H; Tsur E; Patalon T; Beller D; Rimler G; Chodick G; Shohat M
    Prostate; 2024 Jan; 84(1):39-46. PubMed ID: 37842866
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. clinical outcomes of
    Hansen KH; Johansen JS; Urbanska EM; Meldgaard P; Hjorth-Hansen P; Kristiansen C; Stelmach M; Santoni-Rugiu E; Ulhøi MP; Dydensborg AB; Dünweber C; Andersen JL
    Acta Oncol; 2023 Dec; 62(12):1775-1783. PubMed ID: 37815923
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. clinical and prognostic role of sarcopenia based on masticatory muscle index on MR images in patients with extranodal natural killer/T cell lymphoma, nasal type.
    Xu T; Li Y; Liu Y; Ning B; Wu H; Wei Y
    Ann Hematol; 2023 Dec; 102(12):3521-3532. PubMed ID: 37702822
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Adult T-cell leukemia/lymphoma in HTLV-1 non-endemic regions.
    de Mendoza C; Rando A; Miró E; Pena MJ; Rodríguez-Avial I; Ortega D; González-Praetorius A; Reina G; Pintos I; Pozuelo MJ; Soriano V;
    J Clin Virol; 2023 Oct; 167():105578. PubMed ID: 37660433
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. T-cell lymphoma patient harboring BCL11B mutations had favorable overall survival.
    Chen C; Huang L; Liu S; Jiang X; Chen F; Wei X; Guo H; Zeng X; Zeng C; Przybylski GK; Li W; Li Y
    Asia Pac J Clin Oncol; 2024 Feb; 20(1):81-86. PubMed ID: 37635422
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Selinexor With Anti-PD-1 Antibody as a Potentially Effective Regimen for Patients With Natural Killer/T-Cell lymphoma Failing Prior L-Asparaginase and PD-1 Blockade.
    Tao R; Liu C; Zhang W; Zhu Y; Ma Y; Hao S
    Oncologist; 2024 Jan; 29(1):e90-e96. PubMed ID: 37616529
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. clinical outcome of Mantle Cell lymphoma patients with high-risk disease (high-risk MIPI-c or high p53 expression).
    Scheubeck G; Jiang L; Hermine O; Kluin-Nelemans HC; Schmidt C; Unterhalt M; Rosenwald A; Klapper W; Evangelista A; Ladetto M; Jerkeman M; Ferrero S; Dreyling M; Hoster E
    Leukemia; 2023 Sep; 37(9):1887-1894. PubMed ID: 37495776
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. PersonALL: a genetic scoring guide for personalized risk assessment in pediatric B-cell precursor acute lymphoblastic leukemia.
    Bedics G; Egyed B; Kotmayer L; Benard-Slagter A; de Groot K; Bekő A; Hegyi LL; Bátai B; Krizsán S; Kriván G; Erdélyi DJ; Müller J; Haltrich I; Kajtár B; Pajor L; Vojcek Á; Ottóffy G; Ujfalusi A; Szegedi I; Tiszlavicz LG; Bartyik K; Csanádi K; Péter G; Simon R; Hauser P; Kelemen Á; Sebestyén E; Jakab Z; Matolcsy A; Kiss C; Kovács G; Savola S; Bödör C; Alpár D
    Br J Cancer; 2023 Aug; 129(3):455-465. PubMed ID: 37340093
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Leukapheresis and Tisagenlecleucel Manufacturing outcomes in Patients Age <3 Years with Relapsed/Refractory Acute Lymphoblastic Leukemia.
    Fong D; Tiwari R; Acker C; Clough L; Willert J
    Transplant Cell Ther; 2023 Sep; 29(9):579.e1-579.e10. PubMed ID: 37311511
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Epidemiology and a Predictive Model of Prognosis Index Based on Machine Learning in Primary Breast lymphoma: Population-Based Study.
    Yu Y; Xu Z; Shao T; Huang K; Chen R; Yu X; Zhang J; Han H; Song C
    JMIR Public Health Surveill; 2023 Jun; 9():e45455. PubMed ID: 37169516
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Characterization of the input material quality for the production of tisagenlecleucel by multiparameter flow cytometry and its relation to the clinical outcome.
    Štach M; Pytlík R; Šmilauerová K; Rychlá J; Mucha M; Musil J; Koladiya A; Nemec M; Petráčková M; Kaštánková I; Pecherková P; Šrámková L; Polgárová K; Trněný M; Lesný P; Vydra J; Otáhal P
    Pathol Oncol Res; 2023; 29():1610914. PubMed ID: 37151356
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. clinical Analysis of Pediatric T-Cell Acute Lymphoblastic Leukemia Using the MRD-Oriented Strategy System.
    Xue YJ; Wang Y; Lu AD; Jia YP; Zuo YX; Ding MM; Zeng HM; Zhang LP
    Clin Lymphoma Myeloma Leuk; 2023 Jul; 23(7):477-483. PubMed ID: 37080879
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. The prognostic value of controlling nutritional status (CONUT) score-based nomogram on extranodal natural killer/T cell lymphoma patients.
    Zhang S; Sun C; Chen X; Li D; Hu L; Zhang M; Zhang X; Zhang H; Ye J; Wang L; Jia T; Zhu T; Miao Y; Wang C; Wang L; Yan D; Shen Z; Sang W
    Ann Hematol; 2023 Jun; 102(6):1433-1442. PubMed ID: 37074377
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Etiology of oncogenic fusions in 5,190 childhood cancers and its clinical and therapeutic implication.
    Liu Y; Klein J; Bajpai R; Dong L; Tran Q; Kolekar P; Smith JL; Ries RE; Huang BJ; Wang YC; Alonzo TA; Tian L; Mulder HL; Shaw TI; Ma J; Walsh MP; Song G; Westover T; Autry RJ; Gout AM; Wheeler DA; Wan S; Wu G; Yang JJ; Evans WE; Loh M; Easton J; Zhang J; Klco JM; Meshinchi S; Brown PA; Pruett-Miller SM; Ma X
    Nat Commun; 2023 Apr; 14(1):1739. PubMed ID: 37019972
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Multicenter retrospective analysis of clinical outcome of adult patients with mixed-phenotype acute leukemia treated with acute myeloid leukemia-like or acute lymphoblastic leukemia-like chemotherapy and impact of allogeneic stem cell transplantation: a Campus ALL study.
    Lazzarotto D; Tanasi I; Vitale A; Piccini M; Dargenio M; Giglio F; Forghieri F; Fracchiolla N; Cerrano M; Todisco E; Papayannidis C; Leoncin M; Defina M; Guolo F; Pasciolla C; Delia M; Chiusolo P; Mulè A; Candoni A; Bonifacio M; Pizzolo G; Foà R
    Ann Hematol; 2023 May; 102(5):1099-1109. PubMed ID: 36959485
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Germline genetic variations in methotrexate pathway are associated with pharmacokinetics, outcome, and toxicity in patients with primary central nervous system lymphoma.
    Wu Z; Li Z; Qiu X; Zhong M; Ding T
    Expert Rev Clin Pharmacol; 2023 Apr; 16(4):371-381. PubMed ID: 36946320
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 38.